116 related articles for article (PubMed ID: 23208355)
1. Intronic boundary mutation rs430397 cannot affect alternate splicing and is an indecisive risk factor for non-small cell lung cancer.
Zhu X; Fan W; Li D
Chest; 2012 Dec; 142(6):1691-1692. PubMed ID: 23208355
[No Abstract] [Full Text] [Related]
2. GRP78, intronic polymorphisms, and pharmacogenomics in non-small cell lung cancer.
Merrick DT
Chest; 2012 Jun; 141(6):1377-1378. PubMed ID: 22670016
[No Abstract] [Full Text] [Related]
3. An intronic polymorphism in GRP78 improves chemotherapeutic prediction in non-small cell lung cancer.
Zhu X; Lin MCM; Fan W; Tian L; Wang J; Ng SS; Wang M; Kung H; Li D
Chest; 2012 Jun; 141(6):1466-1472. PubMed ID: 21940774
[TBL] [Abstract][Full Text] [Related]
4. Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer.
Kelley MJ; Li S; Harpole DH
J Natl Cancer Inst; 2001 Dec; 93(24):1886-8. PubMed ID: 11752014
[No Abstract] [Full Text] [Related]
5. The Effect of Afatinib Treatment in Non-small Cell Lung Cancer Cells.
Pancewicz-Wojtkiewicz J; Bernatowicz PL
Anticancer Res; 2017 Jul; 37(7):3543-3546. PubMed ID: 28668844
[TBL] [Abstract][Full Text] [Related]
6. Intronic polymorphism (1541-1542delGT) of the constitutive heat shock protein 70 gene has functional significance and shows evidence of association with lung cancer risk.
Rusin M; Zientek H; Krześniak M; Małusecka E; Zborek A; Krzyzowska-Gruca S; Butkiewicz D; Vaitiekunaite R; Lisowska K; Grzybowska E; Krawczyk Z
Mol Carcinog; 2004 Mar; 39(3):155-63. PubMed ID: 14991745
[TBL] [Abstract][Full Text] [Related]
7. Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives.
Haddad FG; Kourie HR; Kattan J
Future Oncol; 2017 Feb; 13(3):201-204. PubMed ID: 27624407
[No Abstract] [Full Text] [Related]
8. Two cases of non-small-cell lung cancer with rare complex mutation of EGFR exon 18 but different response to targeted therapy.
Gauthier H; Douchet G; Lehmann-Che J; Meignin V; Raynaud C; Sabatier P; de Cremoux H; Poirot B; Culine S; Pouessel D; de Cremoux P
J Thorac Oncol; 2014 Oct; 9(10):e78-9. PubMed ID: 25521408
[No Abstract] [Full Text] [Related]
9. Heat Shock Proteins in Non-Small-Cell Lung Cancer-Functional Mechanism.
Zhou G; Pu Y; Zhao K; Chen Y; Zhang G
Front Biosci (Landmark Ed); 2023 Mar; 28(3):56. PubMed ID: 37005758
[TBL] [Abstract][Full Text] [Related]
10. Spatiotemporal T790M heterogeneity in a patient with EGFR-mutant non-small-cell lung cancer.
Hata A; Masago K; Katakami N; Imai Y; Yatabe Y
J Thorac Oncol; 2014 Aug; 9(8):e64-5. PubMed ID: 25157783
[No Abstract] [Full Text] [Related]
11. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.
Han SW; Jeon YK; Lee KH; Keam B; Hwang PG; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ; Kim TY
Pharmacogenet Genomics; 2007 May; 17(5):313-9. PubMed ID: 17429313
[TBL] [Abstract][Full Text] [Related]
12. Biomarker testing in non-small cell lung cancer: a clinician's perspective.
Bernicker E
Arch Pathol Lab Med; 2015 Apr; 139(4):448-50. PubMed ID: 25166873
[No Abstract] [Full Text] [Related]
13. Emerging gene mutation targets in lung cancer.
Johnson BE
Clin Adv Hematol Oncol; 2015 Dec; 13(12):812-4. PubMed ID: 27058846
[No Abstract] [Full Text] [Related]
14. Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.
Cho D; Kocher O; Lee JC; Tenen DG; Meyerson ML; Janne PA; Halmos B
J Clin Oncol; 2005 Jan; 23(1):235-7. PubMed ID: 15625379
[No Abstract] [Full Text] [Related]
15. Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer.
Heuckmann JM; Rauh D; Thomas RK
J Clin Oncol; 2012 Sep; 30(27):3417-20. PubMed ID: 22915655
[No Abstract] [Full Text] [Related]
16. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.
Zhao M; Zhang Y; Cai W; Li J; Zhou F; Cheng N; Ren R; Zhao C; Li X; Ren S; Zhou C; Hirsch FR
Cancer; 2014 Aug; 120(15):2299-307. PubMed ID: 24737648
[TBL] [Abstract][Full Text] [Related]
17. Toward therapies tailored to patient characteristics.
Novello S; Longo M; Levra MG
J Thorac Oncol; 2007 May; 2(5 Suppl):S38-41. PubMed ID: 17457231
[No Abstract] [Full Text] [Related]
18. Unlocking the biological clues of lung cancer.
Hanna N
J Thorac Oncol; 2008 Aug; 3(8):809-10. PubMed ID: 18670296
[No Abstract] [Full Text] [Related]
19. Gefitinib. Still no convincing results in non-small cell lung cancer.
Prescrire Int; 2010 Jun; 19(107):113. PubMed ID: 20738034
[No Abstract] [Full Text] [Related]
20. Young male with fanconi anemia and EGFR-mutant non-small-cell lung cancer.
Cathcart-Rake E; Lopez-Chavez A
J Thorac Oncol; 2014 Nov; 9(11):e83-5. PubMed ID: 25436812
[No Abstract] [Full Text] [Related]
[Next] [New Search]
